EXECUTIVE ENGAGEMENTS
POOL
911
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
182
Interactions with Platform & by Email
PARTICIPANTS
36
Unique # Participated
VALIDATIONS
12
Responses Validated*
COMPANIES
12
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
159
PAGES
201
EDITION
6
PRICE
USD 5600
CODE
MCP22862
*Engagement stats are ongoing and dynamic
Login to access data silos
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Stem Cell Therapy estimated at US$127.5 Million in the year 2020, is projected to reach a revised size of US$242.3 Million by 2027, growing at aCAGR of 9.6% over the period 2020-2027. Allogeneic, one of the segments analyzed in the report, is projected to record 9.9% CAGR and reach US$228.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Autologous segment is readjusted to a revised 5.6% CAGR for the next 7-year period.
The Stem Cell Therapy market in the U.S. is estimated at US$37.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$41.9 Million by the year 2027 trailing a CAGR of 9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.8% and 7.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.
SELECT PLAYERS
Advanced Cell Technology; Anterogen, Ltd.; Biotime, Osiris Therapeutics; Cynata; Cytori Therapeutics; HolostemTerapieAvanzateS.r.l.; Human Longevity; JCR Pharmaceuticals; Medipost; Mesoblastand AlloSource; NuVasive; Osiris Therapeutics, Inc.; Pharmicell; Promethera Biosciences; RTI Surgical; Stemcell Technologies
SEGMENTS
» Type (Allogeneic, Autologous) » Cell Source (Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells, Other Cell Sources) » Application (Musculoskeletal Disorders, Wounds & Injuries, Cardiovascular Diseases, Gastrointestinal Diseases, Other Applications)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Allogeneic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Gastrointestinal Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Musculoskeletal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Wounds & Injuries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Adipose Tissue-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Bone Marrow-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Cord Blood / Embryonic Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cord Blood / Embryonic Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cord Blood / Embryonic Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Cell Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 12 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com